US wants more info on female libido pill

February 11, 2014 by Matthew Perrone

A drugmaker working to develop a pill to boost sexual desire in women says regulators are demanding more studies on the experimental drug.

Sprout Pharmaceuticals said Tuesday that the Food and Drug Administration wants to see more data on how the company's drug, flibanserin, interacts with other medications and how it affects driving ability. Nearly 10 percent of women studied in company trials reported sleepiness while taking the daily pill.

The FDA's request represents another hurdle in the 's 15-year search for a female equivalent to Viagra.

But in a news release, Sprout Pharmaceuticals President Cindy Whitehead described the development as a "significant step toward the approval of flibanserin." The three studies requested by the FDA are relatively small, involving 25 to 50 patients each. The company says it plans to resubmit its to FDA in the third quarter.

The company based in Raleigh, North Carolina, said in December that it had reached an "impasse" with regulators after the agency issued a second rejection letter on the drug. The company filed a formal dispute over the agency's decision, which prompted the FDA's latest request for additional studies.

If approved, Sprout's daily pill would be the first drug for women who report a lack of , a market that drugmakers have been trying to tap since the blockbuster success of Viagra for men in the late 1990s. While earlier drugs worked on hormone levels, flibanserin is the first attempt to increase sexual desire by acting on brain chemicals that affect appetite and mood.

The race to develop a female libido booster was once dominated by multinational companies like Viagra-maker Pfizer Inc. and Procter & Gamble, but today the space mainly consists of tiny startups. Sprout Pharmaceuticals, led by a husband and wife team, acquired flibanserin from Boehringer Ingelheim in 2011, after the German conglomerate abandoned development following an FDA rejection letter. Boehringer studies showed that women taking the drug reported only a modest uptick in "sexually satisfying events."

The FDA's initial rejection followed a 2010 meeting where a panel of expert advisers unanimously voted against the drug, citing its lackluster effectiveness and side effects such as fatigue, dizziness and nausea.

Even if the FDA eventually approves flibanserin, Sprout will have to convince doctors to prescribe the drug for a condition that is still viewed with some skepticism.

The would be specifically approved for premenopausal women with hypoactive sexual desire disorder, described as a lack of sexual appetite that causes emotional distress. Because so many factors affect female sexual appetite, there are a number of other possible causes doctors must rule out before diagnosing the condition, including relationship problems, hormone disorders, depression and mood issues caused by other drugs like sleeping aids and pain medications.

Explore further: Female libido drug remains in limbo (Update)

Related Stories

Female libido drug remains in limbo (Update)

December 11, 2013
The 15-year search for a pill that boosts sexual desire in women has hit another roadblock, raising questions about the future of efforts to develop a female equivalent to Viagra.

Not in the mood but want to be? New studies bring women hope

December 4, 2013
For women, passing midlife can deal a blow to their sex drive. But two new studies just published online in Menopause, the journal of The North American Menopause Society, offer hope to women who want to get their sexual ...

FDA clears first drug for blindness sleep disorder

January 31, 2014
U.S. health regulators have approved a first-of-a-kind drug to treat a sleep disorder that mainly afflicts the blind.

FDA approves first drug for rare erection disorder

December 6, 2013
The Food and Drug Administration has approved the first drug to treat an unusual condition that causes painful, curved erections in men.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.